Literature DB >> 29248774

Presenting Symptoms and Prognostic Factors for Symptomatic Outcomes Following Resection of Meningioma.

Ashley Wu1, Michael A Garcia1, Stephen T Magill2, William Chen1, Harish N Vasudevan1, Arie Perry2, Philip V Theodosopoulos3, Michael W McDermott3, Steve E Braunstein1, David R Raleigh4.   

Abstract

BACKGROUND: Meningioma is the most common primary intracranial tumor and patients present with diverse neurologic symptoms related to meningioma location. This study aimed to systematically quantify the presenting symptoms of meningioma and identify prognostic factors for symptomatic outcome following resection.
METHODS: Two-hundred and eighty-three patients who underwent resection of a total of 313 meningiomas at a single institution were retrospectively identified, including 161 World Health Organization grade I (52.6%), 108 grade II (35.5%), and 37 grade III meningiomas (12.1%). Patient-reported symptoms were extracted from the medical record and dichotomized into acute (<3 months) and long-term (3-12 months) categories. The χ2 test and multivariate regression were used to compare groups.
RESULTS: Patients presented primarily with headaches (48.2%) and either cerebral dysfunctions (48.5%) with convexity meningiomas or cranial nerve deficits (38.9%) with skull base meningiomas. Symptomatic improvement in the acute postoperative period was significantly correlated with long term symptomatic improvement (P ≤ 0.01). Headaches and seizures had the greatest rates of symptomatic improvement after surgery (78%), and the vast majority of patients with symptom improvement experienced complete resolution (86%). In contrast, symptoms persisted in >60% of patients with anosmia, sensory changes, or frontal, temporal, or cerebellar symptoms. Multivariate regression identified subtotal resection as a prognostic factor for persistent symptoms (odds ratio, 0.62; 95% confidence interval, 0.03-1.21; P = 0.041).
CONCLUSIONS: Symptoms improve in the majority of patients after resection of meningioma, with the rate of improvement varying according to symptom type and extent of resection. These data may be a useful when counseling patients about symptoms after resection of meningiomas. Published by Elsevier Inc.

Entities:  

Keywords:  Meningioma; Quality of life; Symptoms

Mesh:

Year:  2017        PMID: 29248774     DOI: 10.1016/j.wneu.2017.12.012

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  12 in total

1.  Olfactory Outcomes after Resection of Tuberculum Sella and Planum Sphenoidale Meningiomas via a Transcranial Approach.

Authors:  Ronak Ved; Matthew Mo; Caroline Hayhurst
Journal:  J Neurol Surg B Skull Base       Date:  2021-01-21

2.  Meningioma-related subacute subdural hematoma: A case report.

Authors:  Daniela Matos; Ricardo Pereira
Journal:  Surg Neurol Int       Date:  2020-08-29

3.  Risk factors for postoperative pneumonia in patients with posterior fossa meningioma after microsurgery.

Authors:  Yong Deng; Chenghong Wang; Yuekang Zhang
Journal:  Heliyon       Date:  2020-05-08

4.  Postoperative seizures in meningioma patients: improving patient selection for antiepileptic drug therapy.

Authors:  Abdurrahman I Islim; Arousa Ali; Ananyo Bagchi; Mohammad U Ahmad; Samantha J Mills; Emmanuel Chavredakis; Andrew R Brodbelt; Michael D Jenkinson
Journal:  J Neurooncol       Date:  2018-06-29       Impact factor: 4.130

5.  Preoperative and postoperative prediction of long-term meningioma outcomes.

Authors:  Efstathios D Gennatas; Ashley Wu; Steve E Braunstein; Olivier Morin; William C Chen; Stephen T Magill; Chetna Gopinath; Javier E Villaneueva-Meyer; Arie Perry; Michael W McDermott; Timothy D Solberg; Gilmer Valdes; David R Raleigh
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

6.  Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years.

Authors:  Elizabeth M Ward; Recinda L Sherman; S Jane Henley; Ahmedin Jemal; David A Siegel; Eric J Feuer; Albert U Firth; Betsy A Kohler; Susan Scott; Jiemin Ma; Robert N Anderson; Vicki Benard; Kathleen A Cronin
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

7.  The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma.

Authors:  Jade Lyons Rimmer; Emanuela Ercolano; Daniele Baiz; Mahindra Makhija; Allison Berger; Todd Sells; Steve Stroud; David Hilton; Claire L Adams; C Oliver Hanemann
Journal:  Cancers (Basel)       Date:  2020-06-30       Impact factor: 6.639

8.  Proliferative Potential, and Inflammatory Tumor Microenvironment in Meningioma Correlate with Neurological Function at Presentation and Anatomical Location-From Convexity to Skull Base and Spine.

Authors:  Johannes Wach; Tim Lampmann; Ági Güresir; Hartmut Vatter; Ulrich Herrlinger; Albert Becker; Silvia Cases-Cunillera; Michael Hölzel; Marieta Toma; Erdem Güresir
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

Review 9.  Health-related quality of life in meningioma.

Authors:  Sameah Haider; Martin J B Taphoorn; Katharine J Drummond; Tobias Walbert
Journal:  Neurooncol Adv       Date:  2021-06-26

10.  Scalp dysesthesia, more than skin deep.

Authors:  Ramsay D McConnell; Gabrielle E Duprat; Jeffery A Cohen; Nicole C Pace
Journal:  JAAD Case Rep       Date:  2022-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.